The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy.
F. A. Holmes
Consultant or Advisory Role - Philips Healthcare
Honoraria - Genentech; Novartis
Y. M. Nagarwala
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
V. A. Espina
No relevant relationships to disclose
L. A. Liotta
No relevant relationships to disclose
M. A. Danso
No relevant relationships to disclose
R. I. Gallagher
No relevant relationships to disclose
K. McIntyre
No relevant relationships to disclose
C. R. C. Osborne
No relevant relationships to disclose
J. M. Mahoney
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
A. M. Florance
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
T. C. Anderson
No relevant relationships to disclose
J. O'Shaughnessy
Honoraria - Genentech; GlaxoSmithKline